Assessing the Clinical Significance of Major (MMR) and Deep (DMR) Molecular Responses for Overall (OS), Progression-Free (PFS) and Event-Free (EFS) Survival in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)